Report Description:
The nuclear medicine/radiopharmaceuticals market is projected to reach
USD 7.27 billion by 2021 from USD 4.67 billion in 2016, growing at a
CAGR of 9.3% in the next five years (2016 to 2021). Over the years, the
nuclear medicine/radiopharmaceuticals market has witnessed various
advancements in radiopharmaceuticals. The market is in its growth phase
with an increasing number of radioisotope approvals for different
clinical indications. Ra-223, I-131, and Y-90 ensured their leading
position in the nuclear medicine therapeutic market.
Reasons to Buy the Report:
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps firms to garner a greater market shares. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.
Table Of Contents:
1 INTRODUCTION 15
2 RESEARCH METHODOLOGY 19
3 EXECUTIVE SUMMARY 28
4 PREMIUM INSIGHTS 33
5 MARKET OVERVIEW 36
6 INDUSTRY TRENDS 46
